Novartis

Novartis
Basel, North West Switzerland
Web: Novartis external link
Ort: Basel
Verwandt mit:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
#display_name

Medizin 25.7
Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana In developed countries, the survival rate for childhood cancer is 80%, while in developing countries it can be as low as 10% Sandoz is committed to working with key stakeholders to pioneer novel ways of expanding access
Medizin 21.7

Novartis receives positive CHMP opinion for Rydapt (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Recommendation

Medizin 14.7

Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy and safety profile in psoriasis 5 year data from long-term Phase III extension

Medizin 6.7

Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx versus Stelara in psoriasis , -   Update also includes use of Cosentyx in moderate-to-severe scal

Wirtschaft 18.7

Net sales in line with prior year (0% cc , -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications Entresto (U

Medizin 13.7

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL Recommendation based on review of CTL019 r/r

Medizin 29.6

In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance -   Zykadia benefit was also seen in pati




 
 
Logo Careerjet